What is Age-Related Macular Degeneration (AMD)?
AMD is a progressive eye disease that affects over 200 million people, mostly those aged 50 and above.
In the early stages, people with AMD have issues seeing in low light, and eventually may see blurry or blank spots in the center of their vision.
This can make it harder to do everyday activities like seeing faces, driving, or reading. There's a significant need for better treatments for people at all stages of this disease.
This can make it harder to do everyday activities like seeing faces, driving, or reading. There's a significant need for better treatments for people at all stages of this disease.
About the Study
Character Bio is conducting the largest, longitudinal genomic study of AMD patients to understand the genetic drivers of progression in people with AMD. Our mission is to treat AMD before the onset of irreversible vision loss.
What’s Involved
Talk to a Character Researcher by phone
Consent to participate and allow sharing of health information
Provide a saliva sample
Receive remuneration
Saliva Collection Instructions
© DNA Genotek, Inc. All rights reserved.
Interim Results
After reaching a major milestone in our study by enrolling the first 5,000 patients, we’re thrilled to share key insights from our discoveries so far, along with exciting details about our plans for potential new AMD therapies.
Click below to download our interim results booklet.
*References
"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis". Wan Ling Wong, Xinyi Su, Xiang Li, Chui Ming G Cheung, Ronald Klein, Ching-Yu Chen, Tien Yin Wong. The Lancet. Volume 2, No. 2, e106–e116, February 2014.
"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis". Wan Ling Wong, Xinyi Su, Xiang Li, Chui Ming G Cheung, Ronald Klein, Ching-Yu Chen, Tien Yin Wong. The Lancet. Volume 2, No. 2, e106–e116, February 2014.